SEGMENT AND GEOGRAPHIC INFORMATION

3 Months Ended

Mar. 31, 2020

The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.

•

The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.


•	The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.

The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.

The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by each reportable segment for the three months ended March 31, 2020 and 2019 are as follows:



	Three Months Ended March 31,
	2020			2019
	(In thousands)
Segment Net Sales
Codman Specialty Surgical	$	231,440		$	234,568
Orthopedics and Tissue Technologies	122,884			125,122
Total revenues	$	354,324		$	359,690
Segment Profit
Codman Specialty Surgical	$	87,235		$	91,380
Orthopedics and Tissue Technologies	31,271			40,495
Segment profit	118,506			131,875
Amortization	(6,977		)	(5,279)
Corporate and other	(84,426		)	(94,288		)
Operating income	$	27,103		$	32,308

The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment.

The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:



	Three Months Ended March 31,
	2020		2019
	(In thousands)
United States	$	246,852	$	256,726
Europe	45,896		48,640
Asia Pacific	39,960		35,700
Rest of World	21,616		18,624
Total Revenues	$	354,324	$	359,690